Adjuvant Pembrolizumab for Melanoma — Approval Imminent?

Pembrolizumab is poised to join the ranks of ipilimumab and nivolumab as adjuvant therapy for patients with stage III melanoma, after showing a 43% reduction in risk for recurrence.
Medscape Medical News

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply